Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:4944 |
Name | gastroesophageal junction adenocarcinoma |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer gastroesophageal cancer gastroesophageal adenocarcinoma gastroesophageal junction adenocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
ERBB2 amp | Trastuzumab | gastroesophageal junction adenocarcinoma | sensitive | detail... |
Unknown unknown | Paclitaxel + Ramucirumab | gastroesophageal junction adenocarcinoma | not applicable | detail... |
Unknown unknown | Ramucirumab | gastroesophageal junction adenocarcinoma | not applicable | detail... |
ERBB2 over exp | Epertinib | gastroesophageal junction adenocarcinoma | sensitive | detail... |
ERBB2 amp | Lapatinib | gastroesophageal junction adenocarcinoma | no benefit | detail... |
Unknown unknown | Erlotinib + Glesatinib | gastroesophageal junction adenocarcinoma | not applicable | detail... |
ERBB2 positive | MM-111 + Paclitaxel + Trastuzumab | gastroesophageal junction adenocarcinoma | no benefit | detail... |
ERBB2 positive | Ado-trastuzumab emtansine | gastroesophageal junction adenocarcinoma | no benefit | detail... |
Unknown unknown | Rivoceranib | gastroesophageal junction adenocarcinoma | not applicable | detail... |
Unknown unknown | Ipilimumab | gastroesophageal junction adenocarcinoma | no benefit | detail... |
Unknown unknown | Napabucasin + Paclitaxel | gastroesophageal junction adenocarcinoma | not applicable | detail... |
Unknown unknown | Zenocutuzumab | gastroesophageal junction adenocarcinoma | not applicable | detail... |
ERBB2 amp SRC E527K | Lapatinib | gastroesophageal junction adenocarcinoma | resistant | detail... |
ERBB2 amp SRC E527K | Lapatinib + Saracatinib | gastroesophageal junction adenocarcinoma | sensitive | detail... |
ERBB2 mutant | Neratinib | gastroesophageal junction adenocarcinoma | no benefit | detail... |
ERBB2 D769Y | Neratinib | gastroesophageal junction adenocarcinoma | predicted - resistant | detail... |
ERBB2 R678Q | Neratinib | gastroesophageal junction adenocarcinoma | predicted - resistant | detail... |
ERBB2 S310F | Neratinib | gastroesophageal junction adenocarcinoma | predicted - sensitive | detail... |
ERBB2 S310Y | Neratinib | gastroesophageal junction adenocarcinoma | predicted - resistant | detail... |
ERBB2 V777L | Neratinib | gastroesophageal junction adenocarcinoma | predicted - resistant | detail... |
ERBB2 over exp | Trastuzumab | gastroesophageal junction adenocarcinoma | sensitive | detail... |
Unknown unknown | Oxaliplatin + Ramucirumab + Tegafur-gimeracil-oteracil Potassium | gastroesophageal junction adenocarcinoma | no benefit | detail... |
Unknown unknown | Camrelizumab + Rivoceranib | gastroesophageal junction adenocarcinoma | not applicable | detail... |
Unknown unknown | Trifluridine-tipiracil hydrochloride | gastroesophageal junction adenocarcinoma | not applicable | detail... |
ERBB2 positive | Afatinib | gastroesophageal junction adenocarcinoma | predicted - sensitive | detail... |
ERBB2 positive | Afatinib + Trastuzumab | gastroesophageal junction adenocarcinoma | predicted - sensitive | detail... |
Unknown unknown | Capecitabine + Nivolumab + Oxaliplatin + Tegafur-gimeracil-oteracil Potassium | gastroesophageal junction adenocarcinoma | not applicable | detail... |
Unknown unknown | Nintedanib | gastroesophageal junction adenocarcinoma | not applicable | detail... |
ERBB2 amp | Trastuzumab deruxtecan | gastroesophageal junction adenocarcinoma | sensitive | detail... |
Unknown unknown | Envafolimab + Fluorouracil + Leucovorin + Oxaliplatin | gastroesophageal junction adenocarcinoma | not applicable | detail... |
ERBB2 over exp | Trastuzumab deruxtecan | gastroesophageal junction adenocarcinoma | sensitive | detail... |
Unknown unknown | ALX148 + Trastuzumab | gastroesophageal junction adenocarcinoma | not applicable | detail... |
Unknown unknown | Lenvatinib + Pembrolizumab | gastroesophageal junction adenocarcinoma | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00313599 | Phase I | Lapatinib + Paclitaxel | Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT00702884 | Phase II | Sunitinib | Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer | Completed | USA | 0 |
NCT00780494 | Phase II | Bevacizumab + Capecitabine + Carboplatin | Ph II of Capecitabine, Carboplatin and Bevacizumab for Gastroesophageal Junction and Gastric Carcinoma | Completed | USA | 0 |
NCT01174121 | Phase II | Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Suspended | USA | 0 |
NCT01183559 | Phase I | Carboplatin + Fluorouracil + Paclitaxel + Vandetanib | A Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery | Completed | USA | 0 |
NCT01191697 | Phase II | Bevacizumab + Trastuzumab Capecitabine + Oxaliplatin | CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer | Active, not recruiting | USA | 0 |
NCT01196390 | Phase III | Carboplatin + Paclitaxel + Trastuzumab Carboplatin + Paclitaxel | Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer | Active, not recruiting | USA | 0 |
NCT01212822 | Phase II | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer | Completed | USA | 0 |
NCT01307956 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab | Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer | Terminated | USA | 0 |
NCT01325441 | Phase Ib/II | Napabucasin + Paclitaxel | A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies | Active, not recruiting | USA | CAN | 0 |
NCT01450696 | Phase III | Capecitabine + Cisplatin + Trastuzumab | HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer | Terminated | USA | 24 |
NCT01490749 | Phase I | Carboplatin + Cetuximab + Everolimus + Paclitaxel | Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer | Completed | USA | 0 |
NCT01526473 | Phase I | AVX901 | A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 | Completed | USA | 0 |
NCT01576666 | Phase Ib/II | Buparlisib + Sonidegib | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | Completed | USA | CAN | 6 |
NCT01641939 | Phase III | Docetaxel Paclitaxel Ado-trastuzumab emtansine | A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer | Terminated | USA | CAN | 26 |
NCT01662869 | Phase III | Onartuzumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric) | Completed | USA | CAN | 22 |
NCT01747551 | Phase II | Aflibercept Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer | Completed | USA | 0 |
NCT01774786 | Phase III | Pertuzumab Capecitabine + Cisplatin + Fluorouracil + Trastuzumab | A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer | Completed | USA | CAN | 30 |
NCT01774851 | Phase II | MM-111 + Paclitaxel + Trastuzumab Paclitaxel + Trastuzumab | A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach | Terminated | USA | 0 |
NCT01803282 | Phase I | Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab | Safety and Tolerability Study in Solid Tumors | Completed | USA | 0 |
NCT01896531 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ipatasertib | A Study of GDC-0068 in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer | Active, not recruiting | USA | 10 |
NCT01913639 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Regorafenib | FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer | Completed | USA | 0 |
NCT01920061 | Phase I | Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib | A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) | Completed | USA | CAN | 3 |
NCT01928290 | Phase II | Trastuzumab Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer | Completed | USA | 0 |
NCT02013154 | Phase I | DKN-01 + Paclitaxel | A Study of DKN-01 in Combination With Paclitaxel | Active, not recruiting | USA | 0 |
NCT02016534 | Phase II | AMG 337 | Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors | Terminated | USA | CAN | 16 |
NCT02024607 | Phase Ib/II | Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer | Completed | USA | CAN | 0 |
NCT02065765 | Phase II | Ramucirumab | International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer | No longer available | 5 | |
NCT02082210 | Phase Ib/II | Emibetuzumab + Ramucirumab | A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | Completed | USA | 0 |
NCT02138929 | Phase I | Everolimus + Sonidegib | LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma | Completed | USA | 0 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02178956 | Phase III | Napabucasin Paclitaxel | A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer | Completed | USA | CAN | 20 |
NCT02187848 | Phase Ib/II | SAR408701 | Evaluation of SAR408701 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | CAN | 3 |
NCT02213289 | Phase Ib/II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Docetaxel + Fluorouracil Trastuzumab Fluorouracil + Irinotecan + Leucovorin Rilotumumab | PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression | Active, not recruiting | USA | 0 |
NCT02234180 | Phase II | Regorafenib | Study of Adjuvant Regorafenib vs Placebo in Patients With Node Positive Esophageal Cancer That Completed Pre-operative Therapy | Terminated | USA | 0 |
NCT02234596 | Phase II | Nintedanib | Nintedanib in Patients With Advanced Esophagogastric Cancer | Completed | USA | 0 |
NCT02241720 | Phase II | Regorafenib | Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers | Terminated | USA | 0 |
NCT02264678 | Phase Ib/II | AZD6738 AZD6738 + Carboplatin AZD6738 + Durvalumab AZD6738 + Olaparib | Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents | Recruiting | USA | 3 |
NCT02268825 | Phase Ib/II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab | Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers | Terminated | USA | 0 |
NCT02274012 | Phase II | Afatinib + Paclitaxel | Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment of HER2 Amplified Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer | Withdrawn | 0 | |
NCT02283359 | Phase I | Irinotecan + Selinexor | Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus | Terminated | USA | 0 |
NCT02314117 | Phase III | Capecitabine Fluorouracil Cisplatin Ramucirumab | A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer | Completed | USA | CAN | 18 |
NCT02317991 | Phase II | Nab-paclitaxel + Ramucirumab | Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer | Active, not recruiting | USA | 0 |
NCT02318901 | Phase Ib/II | Ado-trastuzumab emtansine + Pembrolizumab Pembrolizumab + Trastuzumab Cetuximab + Pembrolizumab | Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer | Terminated | USA | 0 |
NCT02335411 | Phase II | Cisplatin + Fluorouracil + Pembrolizumab Pembrolizumab | A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) | Active, not recruiting | 0 | |
NCT02340975 | Phase Ib/II | Durvalumab Tremelimumab | A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma | Completed | USA | CAN | 4 |
NCT02344810 | Phase Ib/II | AMG 337 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer | Withdrawn | USA | 0 |
NCT02358863 | Phase I | Docetaxel + Irinotecan Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Cisplatin + Docetaxel Cisplatin + Irinotecan Docetaxel + Epirubicin Capecitabine + Docetaxel | Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach (mEGA) | Terminated | USA | 0 |
NCT02389751 | Phase I | Carboplatin Paclitaxel Ganetespib | A Study of Ganetespib in Combination With Chemoradiation | Completed | USA | 0 |
NCT02443324 | Phase I | Pembrolizumab + Ramucirumab | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium | Active, not recruiting | USA | 5 |
NCT02443883 | Phase II | Ramucirumab | A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer | Completed | USA | 11 |
NCT02460224 | Phase Ib/II | LAG525 Spartalizumab | Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | Completed | USA | CAN | 10 |
NCT02488759 | Phase Ib/II | Nivolumab | A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358) | Active, not recruiting | USA | 10 |
NCT02494583 | Phase III | Capecitabine Cisplatin + Fluorouracil Pembrolizumab | Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) | Active, not recruiting | 0 | |
NCT02500043 | Phase III | Trifluridine-tipiracil hydrochloride | Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer | Completed | USA | CAN | 16 |
NCT02509507 | Phase I | Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab | Recruiting | USA | 8 |
NCT02514551 | Phase II | Paclitaxel Ramucirumab | A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer | Completed | USA | CAN | 9 |
NCT02530437 | Phase Ib/II | Taladegib Carboplatin + Paclitaxel | A Phase 1B/2 Study of LY2940680 in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction | Active, not recruiting | USA | 0 |
NCT02545504 | Phase III | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Andecaliximab | GS-5745 With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Completed | USA | 15 |
NCT02551055 | Phase I | Docetaxel Paclitaxel Alisertib Mivavotinib MLN1117 | MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma | Terminated | USA | 1 |
NCT02559687 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180) | Active, not recruiting | 0 | |
NCT02564263 | Phase III | Pembrolizumab Docetaxel + Irinotecan + Paclitaxel | Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) | Active, not recruiting | 0 | |
NCT02564900 | Phase I | Trastuzumab deruxtecan | Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors | Active, not recruiting | USA | 1 |
NCT02572687 | Phase I | Durvalumab + Ramucirumab | A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies | Completed | USA | 7 |
NCT02574663 | Phase I | Gemcitabine + Nab-paclitaxel Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Umbralisib | TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors | Completed | USA | 0 |
NCT02597036 | Phase I | LY3127804 Ramucirumab | A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors | Completed | USA | 3 |
NCT02599324 | Phase Ib/II | Cetuximab + Ibrutinib Ibrutinib + Paclitaxel Everolimus + Ibrutinib Docetaxel + Ibrutinib | A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | Active, not recruiting | USA | 3 |
NCT02625610 | Phase III | Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Avelumab Capecitabine + Oxaliplatin | Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100) | Active, not recruiting | USA | CAN | 15 |
NCT02625623 | Phase III | Avelumab Paclitaxel Irinotecan | Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) | Completed | USA | 9 |
NCT02658214 | Phase I | Cisplatin + Durvalumab + Fluorouracil + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab Carboplatin + Durvalumab + Gemcitabine + Tremelimumab | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | Completed | 2 | |
NCT02660034 | Phase I | Pamiparib + Tislelizumab | The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors | Completed | USA | 5 |
NCT02689284 | Phase Ib/II | Margetuximab-cmkb + Pembrolizumab | Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer | Active, not recruiting | USA | CAN | 3 |
NCT02715531 | Phase I | Capecitabine Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Gemcitabine + Nab-paclitaxel Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin | A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | Active, not recruiting | USA | 6 |
NCT02726399 | Phase II | Capecitabine + Cisplatin Ramucirumab + Trastuzumab | Ramucirumab With Trastuzumab and Capecitabine/Cisplatin in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer | Terminated | USA | 0 |
NCT02730546 | Phase Ib/II | Carboplatin + Paclitaxel Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab | Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery | Suspended | USA | 0 |
NCT02743494 | Phase III | Nivolumab | Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577) | Active, not recruiting | USA | CAN | 29 |
NCT02744287 | Phase Ib/II | BPX-601 + Rimiducid | Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors | Recruiting | USA | 0 |
NCT02749513 | Phase I | Itraconazole | Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients | Active, not recruiting | USA | 0 |
NCT02773524 | Phase III | Regorafenib | A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (INTEGRATEII) | Recruiting | USA | CAN | 5 |
NCT02830594 | Phase II | Pembrolizumab | Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer | Active, not recruiting | USA | 0 |
NCT02864381 | Phase II | Nivolumab Andecaliximab + Nivolumab | GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma | Completed | USA | 8 |
NCT02872116 | Phase III | Capecitabine + Oxaliplatin Ipilimumab + Nivolumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649) | Active, not recruiting | USA | CAN | 27 |
NCT02892123 | Phase I | Capecitabine + ZW25 ZW25 Paclitaxel + ZW25 Vinorelbine + ZW25 | Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers | Recruiting | USA | CAN | 1 |
NCT02908451 | Phase I | AbGn-107 | A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer | Active, not recruiting | USA | 1 |
NCT02918162 | Phase II | Capecitabine + Epirubicin + Oxaliplatin + Pembrolizumab | Perioperative Chemo and Pembrolizumab in Gastric Cancer | Recruiting | USA | 0 |
NCT02943603 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach | Withdrawn | USA | 0 |
NCT02962063 | Phase Ib/II | Carboplatin + Durvalumab + Paclitaxel | Durvalumab, an Anti-PD-L1 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer | Recruiting | USA | 0 |
NCT02970539 | Phase I | Oraxol + Ramucirumab | Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers | Active, not recruiting | USA | 1 |
NCT02998268 | Phase II | Pembrolizumab Carboplatin + Paclitaxel | Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma | Recruiting | USA | 0 |
NCT03008278 | Phase Ib/II | Olaparib + Ramucirumab | Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery | Recruiting | USA | 0 |
NCT03042611 | Phase III | Rivoceranib | Efficacy and Safety Trial of Apatinib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Patients With Gastric Cancer | Completed | USA | 11 |
NCT03044613 | Phase I | Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Paclitaxel | Nivolumab or Nivolumab/Ipilimumab Prior to Chemoradiation Plus Nivolumab With II/III Gastro/Esophageal Cancer | Recruiting | USA | 0 |
NCT03064490 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab | Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED) | Recruiting | USA | 0 |
NCT03076372 | Phase I | MM-310 | A Study Evaluating MM-310 in Patients With Solid Tumors | Unknown status | USA | 0 |
NCT03095781 | Phase I | Pembrolizumab + XL888 | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | Recruiting | USA | 0 |
NCT03102320 | Phase I | Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin | Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) | Active, not recruiting | USA | CAN | 10 |
NCT03122548 | Phase II | CRS-207 + Pembrolizumab | Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers | Terminated | USA | 0 |
NCT03126110 | Phase Ib/II | INCAGN01876 + Ipilimumab + Nivolumab INCAGN01876 + Nivolumab INCAGN01876 + Ipilimumab | Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | Active, not recruiting | USA | 4 |
NCT03141034 | Phase II | Irinotecan + Ramucirumab | Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma | Recruiting | USA | 0 |
NCT03165994 | Phase II | APX005M + Carboplatin + Paclitaxel | APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers | Recruiting | USA | 0 |
NCT03189719 | Phase III | Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Pembrolizumab | First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590) | Active, not recruiting | USA | CAN | 24 |
NCT03193918 | Phase I | Crenolanib + Paclitaxel + Ramucirumab | Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma | Completed | USA | 0 |
NCT03196232 | Phase II | Epacadostat + Pembrolizumab | Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer | Completed | USA | 0 |
NCT03221426 | Phase III | Capecitabine + Cisplatin Capecitabine + Cisplatin + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | Active, not recruiting | USA | CAN | 22 |
NCT03233724 | Phase Ib/II | Pembrolizumab | Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for, Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas | Recruiting | USA | 0 |
NCT03281369 | Phase Ib/II | Atezolizumab + Cobimetinib Atezolizumab + Cisplatin + Fluorouracil + MTIG7192A Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Cobimetinib + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Linagliptin Atezolizumab + PEGPH20 Atezolizumab + BKT140 Paclitaxel + Ramucirumab Cisplatin + Fluorouracil Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + MTIG7192A | A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) | Recruiting | USA | 9 |
NCT03288350 | Phase II | Cisplatin + Docetaxel + Fluorouracil Avelumab | mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA) | Recruiting | CAN | 0 |
NCT03321630 | Phase II | Lenvatinib + Pembrolizumab | A Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies | Recruiting | USA | 0 |
NCT03330561 | Phase I | PRS-343 | PRS-343 in HER2-Positive Solid Tumors | Recruiting | USA | 0 |
NCT03395847 | Phase I | Pembrolizumab + Ramucirumab Pembrolizumab | A Study of Pembrolizumab Monotherapy or in Combination With Other Agents in Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma | Recruiting | USA | 0 |
NCT03407976 | Phase Ib/II | Pembrolizumab + Rivoceranib | Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies | Terminated | USA | 0 |
NCT03410927 | Phase Ib/II | TAS0728 | A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities | Active, not recruiting | USA | 3 |
NCT03427814 | Phase III | Pamiparib | Study of BGB-290 or Placebo in Patients With Advanced or Inoperable Gastric Cancer | Active, not recruiting | USA | 16 |
NCT03448042 | Phase I | BTRC 4017A | A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers | Recruiting | USA | CAN | 11 |
NCT03488667 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma | Recruiting | USA | 0 |
NCT03504397 | Phase III | Fluorouracil + Leucovorin + Oxaliplatin + Zolbetuximab Fluorouracil + Leucovorin + Oxaliplatin | A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight) | Recruiting | USA | CAN | 18 |
NCT03505320 | Phase II | Zolbetuximab Fluorouracil + Leucovorin + Oxaliplatin + Zolbetuximab Pembrolizumab + Zolbetuximab | A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (ILUSTRO) | Active, not recruiting | USA | 5 |
NCT03511222 | Phase I | Pembrolizumab + Vorolanib Nivolumab + Vorolanib | Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | Terminated | USA | 0 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Recruiting | USA | 0 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03539822 | Phase I | Cabozantinib + Durvalumab | Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA) | Recruiting | USA | 0 |
NCT03588039 | Phase I | Oraxol + Pembrolizumab | Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT03596372 | Phase I | BAY1834942 | Study of BAY1834942 in Patients With Solid Tumors | Active, not recruiting | USA | CAN | 1 |
NCT03604991 | Phase II | Carboplatin + Paclitaxel Nivolumab Carboplatin + Nivolumab + Paclitaxel Ipilimumab + Nivolumab | Carboplatin, Paclitaxel and Radiation Therapy With or Without Nivolumab and Ipilimumab in Treating Participants With Esophageal and Gastroesophageal Junction Adenocarcinoma | Recruiting | USA | 0 |
NCT03610711 | Phase Ib/II | Nivolumab + Relatlimab Nivolumab | REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer (REACTION) | Recruiting | USA | 0 |
NCT03615326 | Phase III | Oxaliplatin + Tegafur-gimeracil-oteracil Potassium + Trastuzumab Capecitabine + Oxaliplatin + Trastuzumab Oxaliplatin + Pembrolizumab + Tegafur-gimeracil-oteracil Potassium + Trastuzumab Cisplatin + Fluorouracil + Trastuzumab Cisplatin + Fluorouracil + Pembrolizumab + Trastuzumab Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab | Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) | Recruiting | USA | 19 |
NCT03639714 | Phase Ib/II | GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab | A Study of a Personalized Neoantigen Cancer Vaccine | Recruiting | USA | 1 |
NCT03641313 | Phase II | Berzosertib + Irinotecan | Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer | Recruiting | USA | 0 |
NCT03653507 | Phase III | Capecitabine + Oxaliplatin Capecitabine + Oxaliplatin + Zolbetuximab | A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW) | Recruiting | USA | CAN | 17 |
NCT03662659 | Phase II | Nivolumab + Relatlimab + Tegafur-gimeracil-oteracil Potassium Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin + Relatlimab Nivolumab + Tegafur-gimeracil-oteracil Potassium Capecitabine + Nivolumab + Oxaliplatin Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Capecitabine + Nivolumab + Oxaliplatin + Relatlimab | An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers | Active, not recruiting | USA | CAN | 15 |
NCT03666273 | Phase I | BAY1905254 BAY1905254 + Pembrolizumab | A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254 | Recruiting | USA | 0 |
NCT03675737 | Phase III | Capecitabine + Oxaliplatin Capecitabine + Oxaliplatin + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil | Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) | Recruiting | USA | CAN | 31 |
NCT03686488 | Phase II | Ramucirumab + Trifluridine-tipiracil hydrochloride | TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | Recruiting | USA | 0 |
NCT03694249 | Phase II | Ifetroban sodium | Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence | Recruiting | USA | 0 |
NCT03694522 | Phase II | Bemarituzumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin | A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT) (FIGHT) | Active, not recruiting | USA | 17 |
NCT03704077 | Phase II | Nivolumab Paclitaxel + Ramucirumab Nivolumab + Paclitaxel Nivolumab + Paclitaxel + Relatlimab Nivolumab + Relatlimab | An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Trherapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cance or Gastroesophageal Junction Adenocarcinoma | Withdrawn | USA | CAN | 12 |
NCT03733990 | Phase Ib/II | FP-1305 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Recruiting | USA | 5 |
NCT03735290 | Phase Ib/II | Pembrolizumab Intuvax + Pembrolizumab | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (ILIAD) | Recruiting | USA | 0 |
NCT03739801 | Phase Ib/II | MM-398 + Ramucirumab | MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | Withdrawn | USA | 0 |
NCT03752398 | Phase I | XmAb23104 | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Recruiting | USA | 0 |
NCT03776487 | Phase Ib/II | Fluorouracil + Oxaliplatin Nivolumab Ipilimumab + Nivolumab Fluorouracil + Ipilimumab + Nivolumab | Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer | Recruiting | USA | 0 |
NCT03777657 | Phase III | Capecitabine + Oxaliplatin Cisplatin + Fluorouracil Capecitabine + Oxaliplatin + Tislelizumab Cisplatin + Fluorouracil + Tislelizumab | Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma | Recruiting | USA | 13 |
NCT03784326 | Phase I | Atezolizumab + Fluorouracil + Oxaliplatin | Atezolizumab, Oxaliplatin, and Fluorouracil in Treating Patients With Esophageal or Gastroesophageal Cancer | Recruiting | USA | 0 |
NCT03809624 | Phase I | INBRX-105 | Study of INBRX-105 in Patients With Solid Tumors (PDL1x41BB) | Recruiting | USA | 0 |
NCT03840967 | Phase II | Niraparib | A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma | Recruiting | USA | 0 |
NCT03849469 | Phase I | Pembrolizumab + XmAb22841 XmAb22841 | A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) | Recruiting | USA | 0 |
NCT03894618 | Phase I | SL-279252 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | Recruiting | USA | CAN | 2 |
NCT03918499 | Phase Ib/II | Cyclophosphamide + IRX-2 + Pembrolizumab | IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer | Recruiting | USA | 0 |
NCT03954704 | Phase I | Fluorouracil + GS-1423 + Leucovorin + Oxaliplatin GS-1423 | Study of GS-1423 in Participants With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT03993873 | Phase I | TPX-0022 | Phase 1 Study of TPX-0022, a MET/CSF1R/SRC Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in MET | Recruiting | USA | 3 |
NCT03995017 | Phase Ib/II | Ramucirumab + Rucaparib Nivolumab + Ramucirumab + Rucaparib | Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma (RiME) | Recruiting | USA | 0 |
NCT03997448 | Phase II | Abemaciclib + Pembrolizumab | Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149 | Active, not recruiting | USA | 0 |
NCT04007744 | Phase I | Pembrolizumab + Sonidegib | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04014075 | Phase II | Trastuzumab deruxtecan | DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02) | Active, not recruiting | USA | 4 |
NCT04018872 | Phase II | Itraconazole | Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer | Recruiting | USA | 0 |
NCT04021108 | Phase II | Nivolumab Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin | Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) | Recruiting | USA | 0 |
NCT04032704 | Phase II | Ladiratuzumab vedotin | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Recruiting | USA | 5 |
NCT04041310 | Phase I | GAd-209-FSP + MVA-209-FSP | Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | Recruiting | USA | 0 |
NCT04044859 | Phase I | ADP-A2M4 cells | Surpass: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Tumors | Recruiting | USA | CAN | 2 |
NCT04060342 | Phase Ib/II | GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | Recruiting | USA | 1 |
NCT04069273 | Phase II | Paclitaxel + Ramucirumab Paclitaxel + Pembrolizumab + Ramucirumab Pembrolizumab | Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma (SEQUEL) (SEQUEL) | Recruiting | USA | 0 |
NCT04082364 | Phase II | Fluorouracil + Leucovorin + Margetuximab-cmkb + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab Capecitabine + Margetuximab-cmkb + Oxaliplatin + Retifanlimab Margetuximab-cmkb + Retifanlimab Capecitabine + Margetuximab-cmkb + MGD013 + Oxaliplatin Capecitabine + Oxaliplatin + Trastuzumab Fluorouracil + Leucovorin + Margetuximab-cmkb + Oxaliplatin + Retifanlimab Capecitabine + Margetuximab-cmkb + Oxaliplatin Fluorouracil + Leucovorin + Margetuximab-cmkb + MGD013 + Oxaliplatin | Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY) | Recruiting | USA | 7 |
NCT04089904 | Phase II | Pembrolizumab | Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma | Recruiting | USA | 0 |
NCT04099641 | Phase II | Bavituximab + Pembrolizumab | An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients | Recruiting | USA | 3 |
NCT04112498 | Phase I | Nivolumab + Relatlimab + rHuPH20 | A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab | Recruiting | USA | 0 |
NCT04114136 | Phase II | Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT04117958 | Phase I | AMG 199 | Study of AMG 199 in Subjects With MUC17-Positive Gastric and Gastroesophageal Junction Cancer | Recruiting | USA | 7 |
NCT04189445 | Phase II | Futibatinib | Futibatinib in Patients With Specific FGFR Aberrations | Recruiting | USA | 13 |
NCT04210115 | Phase III | Cisplatin + Fluorouracil + Pembrolizumab Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Cisplatin + Fluorouracil | Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) | Recruiting | USA | CAN | 23 |
NCT04260191 | Phase I | AMG 910 | Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma | Recruiting | USA | 6 |
NCT04363801 | Phase II | DKN-01 + Tislelizumab Capecitabine + DKN-01 + Oxaliplatin + Tislelizumab | A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer (DisTinGuish) | Recruiting | USA | 1 |
NCT04379596 | Phase II | Cisplatin + Fluorouracil + Trastuzumab Capecitabine + Oxaliplatin + Trastuzumab Capecitabine + Cisplatin + Trastuzumab Trastuzumab deruxtecan Fluorouracil + Oxaliplatin + Trastuzumab Fluorouracil + Trastuzumab deruxtecan Capecitabine + Trastuzumab deruxtecan Durvalumab + Trastuzumab deruxtecan Fluorouracil + Oxaliplatin + Trastuzumab deruxtecan Capecitabine + Oxaliplatin + Trastuzumab deruxtecan Durvalumab + Fluorouracil + Trastuzumab deruxtecan Capecitabine + Durvalumab + Trastuzumab deruxtecan | Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2+ Gastric Cancer (DESTINY-Gastric03) (DG-03) | Recruiting | USA | CAN | 9 |
NCT04383938 | Phase Ib/II | APR-246 + Pembrolizumab | Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT04391049 | Phase I | Carboplatin + OBP-301 + Paclitaxel | Testing the Addition of the Anti-cancer Viral Therapy Telomelysin to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery | Recruiting | USA | 0 |
NCT04396821 | Phase I | TST001 | A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT04430738 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy for HER2+ Gastrointestinal Cancers | Recruiting | USA | 0 |
NCT04442126 | Phase Ib/II | NM21-1480 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT04450732 | Phase I | GQ1001 | Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors | Recruiting | USA | 1 |
NCT04460937 | Phase I | Adavosertib | Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers | Recruiting | USA | 0 |
NCT04467515 | Phase Ib/II | CAM-H2 | A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer | Not yet recruiting | CAN | 0 |
NCT04499924 | Phase II | Paclitaxel + Ramucirumab + Trastuzumab + Tucatinib Paclitaxel + Ramucirumab + Tucatinib Paclitaxel + Ramucirumab | Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer (MOUNTAINEER-02) | Recruiting | USA | 0 |
NCT04510285 | Phase II | Pembrolizumab + Trastuzumab Trastuzumab | Study of Pembrolizumab Plus Trastuzumab or Trastuzumab Alone After Surgery in Patients With Esophagogastric Tumors | Recruiting | USA | 0 |
NCT04521621 | Phase Ib/II | Coxsackievirus A21 + Pembrolizumab | A Study of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | Recruiting | USA | CAN | 5 |
NCT04592913 | Phase III | Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Docetaxel + Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin | Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer | Recruiting | USA | CAN | 14 |
NCT04594811 | Phase II | Nivolumab Nivolumab + NT-I7 | NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma | Recruiting | USA | 0 |
NCT04604132 | Phase Ib/II | Atezolizumab + Derazantinib Derazantinib + Paclitaxel + Ramucirumab Derazantinib Paclitaxel + Ramucirumab | Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma (FIDES-03) | Recruiting | USA | 7 |
NCT04660760 | Phase II | Paclitaxel + Ramucirumab Ramucirumab + Trifluridine-tipiracil hydrochloride | Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer | Not yet recruiting | USA | 0 |
NCT04757363 | Phase II | Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin + Regorafenib | A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer | Recruiting | USA | 0 |
NCT04772989 | Phase I | AB308 + GLS-010 | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies | Not yet recruiting | USA | 0 |